Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Products under Development by Stage of Development | 7 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Products under Development by Therapy Area | 8 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Products under Development by Indication | 9 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Pipeline Products Glance | 10 | 1 |
| Early Stage Products | 10 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Products under Development by Companies | 11 | 2 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Therapeutics Assessment | 13 | 3 |
| Assessment by Monotherapy/Combination Products | 13 | 1 |
| Assessment by Mechanism of Action | 14 | 1 |
| Assessment by Molecule Type | 15 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Companies Involved in Therapeutics Development | 16 | 7 |
| Bristol-Myers Squibb Company | 16 | 1 |
| Curadev Pharma Private Limited | 17 | 1 |
| Globavir Biosciences, Inc. | 18 | 1 |
| IOmet Pharma | 19 | 1 |
| Netherlands Translational Research Center B.V. | 20 | 1 |
| NewLink Genetics Corporation | 21 | 1 |
| Pfizer Inc. | 22 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Drug Profiles | 23 | 12 |
| GBV-1012 Drug Profile | 23 | 1 |
| GBV-1073 Drug Profile | 24 | 1 |
| RG-70099 Drug Profile | 25 | 1 |
| Small Molecule to Inhibit TDO-2 for Oncology Drug Profile | 26 | 2 |
| Small Molecules to Inhibit IDO and TDO for Cancer Drug Profile | 28 | 1 |
| Small Molecules to Inhibit IDO and TDO for Oncology Drug Profile | 29 | 1 |
| Small Molecules to Inhibit IDO/TDO for Oncology Drug Profile | 30 | 1 |
| Small Molecules to Inhibit TDO for Cancer Drug Profile | 31 | 1 |
| Small Molecules to Inhibit TDO for Oncology Drug Profile | 32 | 1 |
| Small Molecules to Inhibit TDO for Oncology Drug Profile | 33 | 1 |
| Small Molecules to Inhibit TDO for Parkinson's Disease Drug Profile | 34 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Dormant Projects | 35 | 1 |
| Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) Featured News &Press Releases | 36 | 2 |
| Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs | 36 | 1 |
| Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium | 36 | 2 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |
